登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由江苏省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07435454,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
70 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically confirmed locally advanced unresectable esophageal squamous cell carcinoma (cTXN+M0 or cT2-T4aNXM0).
入选标准第 1 条
Direct tumor invasion into adjacent organs, such as the aorta or trachea (i.e., T4b disease).
排除标准第 1 条
Participation in a study of an investigational drug or device within 4 weeks prior to the first study treatment.
排除标准第 9 条
History of other malignancy within the past 5 years, except carcinoma in situ of the cervix or basal cell carcinoma.
排除标准第 5 条
Known history of HIV, HBV, or HCV infection.
排除标准第 8 条
Negative urine or serum pregnancy test within 24 hours prior to the first dose of study intervention.
入选标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07435454,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Histologically confirmed locally advanced unresectable esophageal squamous cell carcinoma (cTXN+M0 or cT2-T4aNXM0). Considered eligible for definitive chemoradiotherapy. Age ≥ 70 years and/or intolerant to intravenous chemotherapy due to comorbidities, with severe dysphagia/feeding obstruction. Disease evaluable by qualitative radiologic assessment per the local investigator. Not eligible for curative surgery. Adequate hematologic function, defined as: ANC ≥ 1500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L. Adequate renal function, defined as: creatinine ≤ 1.5 × ULN; or for patients with creatinine > 1.5 × ULN, measured or calculated creatinine clearance ≥ 60 mL/min. Adequate hepatic function, defined as: total bilirubin ≤ 1.5 × ULN; or for patients with total bilirubin > 1.5 × ULN, direct bilirubin ≤ ULN provided ALT/AST ≤ 2.5 × ULN and albumin ≥ 3.0 g/dL. Adequate coagulation function, defined as: INR ≤ 1.5 × ULN, unless the patient is on anticoagulant therapy with PT or aPTT within the therapeutic range. Negative urine or serum pregnancy test within 24 hours prior to the first dose of study intervention. Voluntary participation in the study, signed written informed consent, good compliance, and willingness to comply with follow-up procedures.排除标准:Exclusion Criteria:
Direct tumor invasion into adjacent organs, such as the aorta or trachea (i.e., T4b disease). Prior chemotherapy or radiotherapy for esophageal cancer. Any prior systemic anticancer therapy for esophageal cancer. Major surgery other than feeding tube insertion, open biopsy, or significant trauma within 28 days before randomization, or anticipated major surgery during study treatment. History of other malignancy within the past 5 years, except carcinoma in situ of the cervix or basal cell carcinoma. Gastric fistula or esophageal fistula. Active infection requiring systemic therapy. Known history of HIV, HBV, or HCV infection. Participation in a study of an investigational drug or device within 4 weeks prior to the first study treatment. History of non-infectious pneumonitis requiring corticosteroid therapy, or current pneumonitis. Known hypersensitivity to any study drug. Inability or unwillingness to comply with protocol requirements as assessed by the investigator.
引自 ClinicalTrials.gov, NCT07435454, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07435454,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。